Evotec SE I (EVT.DE)
Discovers and develops drugs for pharmaceutical companies and research institutions.
3.50+0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-49.6%
The outlook
Evotec is trading near its 52-week lows, well below both its 50- and 200-day moving averages, suggesting downward momentum. Analysts lean bullish with an average target about 40% above the current price, though the overall scoring reflects skepticism. The stock's position in its range and trend indicate weakness despite the optimistic price targets.
What’s behind the score
Analyst consensusBuy — 2.4 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Price targetAvg target +40% vs current price
Analyst price target
~12-month · 7 analysts4.90average target+39.8% vs now
Now 3.50
Low 3.50High 10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
7.84
52-wk low
3.18
50-day avg
4.65
200-day avg
5.30
Trailing P/E
—